“Efficacy Outcomes in the Phase 3 COMBI-AD Study of Adjuvant Dabrafenib Plus Trametinib vs Placebo in Patients with Stage III BRAFV600E/K-Mutant Melanoma”, J of Skin, vol. 2, no. S1, p. S43, Feb. 2018, doi: 10.25251/skin.2.supp.43.